Virus inactivation by pepsin treatment at pH 4 of IgG solutions: Factors affecting the rate of virus inactivation

Transfusion

Volumn 36, Issue 10, 1996, Pages 866-872

  Omar, A ^a,b   Kempf, C ^a   Immelmann, A ^a   Rentsch, M ^a   Morgenthaler, J J ^a  

^a Central Laboratory in Bern   (Switzerland)

^b Analysis GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PEPSIN A;

ARTICLE; CATTLE DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; KINETICS; PH; PSEUDORABIES HERPETOVIRUS; SEMLIKI FOREST ALPHAVIRUS; TEMPERATURE DEPENDENCE; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0029801029     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.361097017171.x     Document Type: Article

References (25)

1. Imbach P, Perret B A, Babington R, et al. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang 1991;61:240-3.
2. Kistler P, Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962;7:414-24.
3. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human GGG-globuIin. Vox Sang 1962;7:157-74.
4. Reid KG, Cuthbertson B, Jones AD, Mclntosh RV. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang 1988;55:75-80.
5. Kempf C, Jentsch P, Poirier B, et al. Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991;31:423-7.
6. Kempf C, Jenlsch P, Barré-Sinoussi FB, et al. Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin u (letter). JAcquir Immune DeficSyndr 1991;4:828-30.
7. Hämälainen E, Suomela H, Ukkonen P. Virus inactivation u during intravenous immunoglobulin production. Vox Sang 1992;63:6-11.
8. Burnouf-Radosevich M. [Viral safety of intravenous immunoglobulins G for therapeutic use.] Transfus Clin Biol 1995;2:16779.
9. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin (letter). Lancet 1983;2:974-5.
10. Lever AM, Webster AD, Brown D, Thomas HC. Non-A,non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984;2:1062-4.
11. Lever AM, Webster AD, Brown D, Thomas HC. Non-A,non-B hepatitis after intravenous gammaglobulin (letter). Lancet 1985;1:587.
12. Ochs HD, Fischer SH, Virant FS, et al. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet 1985; 1:404-5.
13. Weiland O, Mattsson L, Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin (letter). Lancet 1986; 1:976-7.
14. Webster AD, Lever AM. Non-A, non-B hepatitis after intravenous gammaglobulin (letter). Lancet 1986;1:322.
15. Ochs HD, Fischer SH, Virant FS, et al. Non-A, non-B hepatitis after intravenous gammaglobulin (letter). Lancet 1986; 1:322-3.
16. Björkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-11.
17. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994;43:505-9.
18. Bader JM. HCV and Gammagard in France. Lancet 1994;343:1628.
19. Gomperts ED. HCV and Gammagard in France (letter). Lancet 1994;344:201.
20. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
21. SchianoTD, Bellary SV, Black M. Possible transmission of hepatitis C virus infection with intravenous immunoglobulin (letter). Ann Intern Med 1995;122:802-3.
22. Müller C, Moritz R, Prigge G, et al. HIV p24 ELISA for quantitation of HIV infection and replication in vitro. Fresenius ZAnalChem 1988:330:352-3.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
24. Nir S, Duzgunes N, de Lima MC, Hoekstra D. Fusion of enveloped viruses with cells and liposomes. Activity and inactivation. CellBiophys 1990;17:181-201.
25. Pedroso de Lima MC, Ramalho-Santos J, Martins MF, et al. Kinetic modeling of Sendai virus fusion with PC-12 cells. Effect of pH and temperature on fusion and viral inactivation. Eur J Biocheml992;205:181-6.